SG11202110683WA - Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof - Google Patents
Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereofInfo
- Publication number
- SG11202110683WA SG11202110683WA SG11202110683WA SG11202110683WA SG11202110683WA SG 11202110683W A SG11202110683W A SG 11202110683WA SG 11202110683W A SG11202110683W A SG 11202110683WA SG 11202110683W A SG11202110683W A SG 11202110683WA SG 11202110683W A SG11202110683W A SG 11202110683WA
- Authority
- SG
- Singapore
- Prior art keywords
- orally
- solid forms
- lactamase inhibitor
- beta
- delivered
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828349P | 2019-04-02 | 2019-04-02 | |
| PCT/US2020/026114 WO2020205932A1 (en) | 2019-04-02 | 2020-04-01 | Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110683WA true SG11202110683WA (en) | 2021-10-28 |
Family
ID=72666564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110683WA SG11202110683WA (en) | 2019-04-02 | 2020-04-01 | Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220194964A1 (en) |
| EP (1) | EP3946364A4 (en) |
| JP (1) | JP2022529212A (en) |
| KR (1) | KR20210146979A (en) |
| CN (1) | CN113905741A (en) |
| AU (1) | AU2020256179A1 (en) |
| BR (1) | BR112021019656A2 (en) |
| CA (1) | CA3135614A1 (en) |
| EA (1) | EA202192669A1 (en) |
| IL (1) | IL286850A (en) |
| MA (1) | MA55557A (en) |
| SG (1) | SG11202110683WA (en) |
| TW (1) | TW202102230A (en) |
| WO (1) | WO2020205932A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2730013T3 (en) | 2013-01-10 | 2019-11-07 | Venatorx Pharmaceuticals Inc | Betalactamase inhibitors |
| RU2686740C2 (en) | 2014-06-11 | 2019-04-30 | Венаторкс Фармасьютикалс, Инк. | Beta-lactamase inhibitors |
| US10399996B2 (en) | 2015-09-11 | 2019-09-03 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2018218190A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| SG11202105505TA (en) * | 2018-11-29 | 2021-06-29 | Venatorx Pharmaceuticals Inc | Combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| KR20230062075A (en) | 2021-10-29 | 2023-05-09 | 코웨이 주식회사 | Evaporator for making ice |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100292185A1 (en) * | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| US9422314B2 (en) * | 2012-12-07 | 2016-08-23 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| RU2686740C2 (en) * | 2014-06-11 | 2019-04-30 | Венаторкс Фармасьютикалс, Инк. | Beta-lactamase inhibitors |
| WO2017100537A1 (en) * | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| SG11202105505TA (en) * | 2018-11-29 | 2021-06-29 | Venatorx Pharmaceuticals Inc | Combination compositions comprising a beta-lactamase inhibitor and uses thereof |
-
2020
- 2020-04-01 CN CN202080041011.8A patent/CN113905741A/en active Pending
- 2020-04-01 MA MA055557A patent/MA55557A/en unknown
- 2020-04-01 EP EP20782987.0A patent/EP3946364A4/en active Pending
- 2020-04-01 TW TW109111383A patent/TW202102230A/en unknown
- 2020-04-01 WO PCT/US2020/026114 patent/WO2020205932A1/en active Application Filing
- 2020-04-01 US US17/599,913 patent/US20220194964A1/en active Pending
- 2020-04-01 JP JP2021557398A patent/JP2022529212A/en active Pending
- 2020-04-01 CA CA3135614A patent/CA3135614A1/en active Pending
- 2020-04-01 BR BR112021019656A patent/BR112021019656A2/en not_active Application Discontinuation
- 2020-04-01 EA EA202192669A patent/EA202192669A1/en unknown
- 2020-04-01 KR KR1020217034942A patent/KR20210146979A/en unknown
- 2020-04-01 AU AU2020256179A patent/AU2020256179A1/en not_active Abandoned
- 2020-04-01 SG SG11202110683WA patent/SG11202110683WA/en unknown
-
2021
- 2021-09-30 IL IL286850A patent/IL286850A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA55557A (en) | 2022-02-09 |
| EA202192669A1 (en) | 2022-03-01 |
| JP2022529212A (en) | 2022-06-20 |
| EP3946364A1 (en) | 2022-02-09 |
| BR112021019656A2 (en) | 2022-01-18 |
| KR20210146979A (en) | 2021-12-06 |
| AU2020256179A1 (en) | 2021-11-18 |
| EP3946364A4 (en) | 2023-01-18 |
| CA3135614A1 (en) | 2020-10-08 |
| IL286850A (en) | 2021-10-31 |
| WO2020205932A1 (en) | 2020-10-08 |
| CN113905741A (en) | 2022-01-07 |
| TW202102230A (en) | 2021-01-16 |
| US20220194964A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286850A (en) | Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof | |
| EP3684361A4 (en) | Substituted inhibitors of menin-mll and methods of use | |
| IL289879A (en) | Solid forms of an hpk1 inhibitor | |
| EP3968999A4 (en) | Fgfr inhibitors and methods of use thereof | |
| EP3810617A4 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| EP3962481A4 (en) | Kcnt1 inhibitors and methods of use | |
| EP3962479A4 (en) | Kcnt1 inhibitors and methods of use | |
| EP3969439A4 (en) | Acss2 inhibitors and methods of use thereof | |
| EP3741758A4 (en) | Bromodomain inhibitor compound and use thereof | |
| EP4041198A4 (en) | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof | |
| EP3986894A4 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| SG11202106690QA (en) | Methods of characterizing condensate-associated characteristics of compounds and uses thereof | |
| EP3846808A4 (en) | Papd5 inhibitors and methods of use thereof | |
| EP3893891A4 (en) | Solid forms of a cd73 inhibitor and the use thereof | |
| EP3784650A4 (en) | Novel mct4 inhibitors and uses thereof | |
| EP3959197A4 (en) | Papd5 inhibitors and methods of use thereof | |
| EP3836938A4 (en) | Solid forms of substituted benzoxaborole and compositions thereof | |
| IL286832A (en) | Inhibitors of aldose reductase | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| EP3765485A4 (en) | Immuno-exosomes and methods of use thereof | |
| EP3761989A4 (en) | Imidazodiazepinediones and methods of use thereof | |
| EP3870181A4 (en) | Crystal forms of an alk2 inhibitor | |
| EP3793552C0 (en) | Abhd12 inhibitors and methods of making and using same | |
| EP3749638A4 (en) | Synthesis of 4-chlorokynurenines and intermediates | |
| EP4025197A4 (en) | Inhibitors of sglt and uses thereof |